Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Fig. 7

FDA-approved therapeutic drugs for urologic cancers. a Distribution of therapeutic drugs for urologic cancers during the past 31 years (adapted from [867]). b Recombinant human IL-2 (obtained from www.rcsb.org and go.drugbank.com). c Multitarget TKI and VEGFR inhibitors. d mTOR inhibitors. e PDL1-directed mAbs. f Nectin-4-directed ADC. g DNA topoisomerase inhibitor. h FGFR inhibitor

Back to article page